Is pulmonary hypertension a metabolic disease?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Novel methods in pulmonary hypertension phenotyping in the age of precision medicine (2015 Grover Conference series).Pulmonary circulation · 2016
   Review
2. Bone Morphogenic Protein Type 2 Receptor Mutation-Independent Mechanisms of Disrupted Bone Morphogenetic Protein Signaling in Idiopathic Pulmonary Arterial Hypertension.American journal of respiratory cell and molecular biology · 2016
   Article
3. Sildenafil reduces signs of oxidative stress in pulmonary arterial hypertension: Evaluation by fatty acid composition, level of hydroxynonenal and heart rate variability.Redox biology · 2016
   Article
4. Plasma metabolomic profile in chronic thromboembolic pulmonary hypertension.Pulmonary circulation
   Article

Corrections and comments

• Comment on
  The sphingosine kinase 1/sphingosine-1-phosphate pathway in pulmonary arterial hypertension.2014

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as